Why the study?
Clinical and pharmacological factors can impair gastrointestinal absorption of oral P2Y12 inhibitors, underscoring the need for novel agents or routes of administration with more favorable pharmacokinetic and pharmacodynamic profiles.
Selatogrel is a novel P2Y12 inhibitor with promising pharmacological properties that warrants further investigation in phase 3 clinical trials.
Answers are grounded in this paper and cite their sources.
Supports phase 3 evaluation of selatogrel; leaves open its clinical efficacy and safety versus existing P2Y12 inhibitors.
INTRODUCTION: receptor antagonists, but numerous clinical and pharmacological factors can lead to impaired gastrointestinal absorption resulting in reduced antithrombotic protection. These observations underscore the need for novel compounds or routes of administration that enable more favorable pharmacokinetic and pharmacodynamic profiles while reducing the risk for thrombotic complications. AREAS COVERED: inhibitors. Such findings make selatogrel a promising agent to be tested in phase 3 studies. EXPERT OPINION: inhibitor and the association with concomitant drugs.
No takes yet. Share an insight, caveat, or question.
Milluzzo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: